LIM Kinase 1 (LIMK1) Human shRNA Plasmid Kit (Locus ID 3984)
CAT#: TR320403
LIMK1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 1 publication. |
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
经常一起买 (2)
LIMK1 (LIM Kinase 1 ) mouse monoclonal antibody, clone OTI6B4 (formerly 6B4)
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | LIM Kinase 1 (LIMK1) Human shRNA Plasmid Kit (Locus ID 3984) |
Locus ID | 3984 |
UniProt ID | P53667 |
Synonyms | LIMK; LIMK-1 |
Vector | pRS |
Format | Retroviral plasmids |
Kit Components | LIMK1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 3984). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | NM_001204426, NM_002314, NM_016735, NM_002314.1, NM_002314.2, NM_002314.3, NM_001204426.1, BC148340, BC152982, NM_001204426.2, NM_002314.4 |
Summary | There are approximately 40 known eukaryotic LIM proteins, so named for the LIM domains they contain. LIM domains are highly conserved cysteine-rich structures containing 2 zinc fingers. Although zinc fingers usually function by binding to DNA or RNA, the LIM motif probably mediates protein-protein interactions. LIM kinase-1 and LIM kinase-2 belong to a small subfamily with a unique combination of 2 N-terminal LIM motifs and a C-terminal protein kinase domain. LIMK1 is a serine/threonine kinase that regulates actin polymerization via phosphorylation and inactivation of the actin binding factor cofilin. This protein is ubiquitously expressed during development and plays a role in many cellular processes associated with cytoskeletal structure. This protein also stimulates axon growth and may play a role in brain development. LIMK1 hemizygosity is implicated in the impaired visuospatial constructive cognition of Williams syndrome. Alternative splicing results in multiple transcript variants encoding distinct isoforms.[provided by RefSeq, Feb 2011] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects
,Eva M Jimenez-Mateos, Tobias Engel, Paula Merino-Serrais, Ross C McKiernan, Katsuhiro Tanaka, Genshin Mouri, Takanori Sano, Colm O'Tuathaigh, John L Waddington, Suzanne Prenter, Norman Delanty, Michael A Farrell, Donncha F O'Brien, Ronán M Conroy, Raymond L Stallings, Javier DeFelipe & David C Henshall,
Nature Medicine 18, 1087-1094 doi:10.1038/nm.2834
[LIMK1]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...